HDAC inhibitors as epigenetic regulators for cancer immunotherapy

Mariarosaria Conte, Raffaele De Palma, Lucia Altucci

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

In recent years, anti-tumor immunotherapy has shown promising results, and immune-oncology is now emerging as the fourth major wave in the treatment of tumors after radiotherapy, chemotherapy and molecular targeted therapy. Understanding the impact of the immune system on neoplastic cells is crucial to improve its effectiveness against cancer. The stratification of patients who might benefit from immunotherapy as well as the personalization of medicine have contributed to the discovery of new immunotherapeutic targets and molecules. In the present review, we discuss the mechanistic role of histone deacetylase inhibitors (HDACi) as potential immunomodulating agents to treat cancer. Our current understanding of the use of HDACi in combination with various immunotherapeutic approaches, such as immunomodulating agents and cancer vaccines, is also addressed. The potential clinical applications of the growing number of novel epigenetic drugs for cancer immunotherapy are widening, and some of these therapies are already in clinical trials.

Original languageEnglish
Pages (from-to)65-74
Number of pages10
JournalInternational Journal of Biochemistry and Cell Biology
Volume98
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Histone Deacetylase Inhibitors
Epigenomics
Immunotherapy
Tumors
Cancer Vaccines
Oncology
Chemotherapy
Immune system
Radiotherapy
Medicine
Neoplasms
Molecules
Molecular Targeted Therapy
Pharmaceutical Preparations
Immune System
Clinical Trials
Drug Therapy
Therapeutics

Keywords

  • Cancer
  • Epigenetics
  • Histone deacetylases
  • Immune evasion
  • Immunotherapy

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

HDAC inhibitors as epigenetic regulators for cancer immunotherapy. / Conte, Mariarosaria; De Palma, Raffaele; Altucci, Lucia.

In: International Journal of Biochemistry and Cell Biology, Vol. 98, 01.05.2018, p. 65-74.

Research output: Contribution to journalReview article

@article{216a68e8225a4ceea3084f84eee46021,
title = "HDAC inhibitors as epigenetic regulators for cancer immunotherapy",
abstract = "In recent years, anti-tumor immunotherapy has shown promising results, and immune-oncology is now emerging as the fourth major wave in the treatment of tumors after radiotherapy, chemotherapy and molecular targeted therapy. Understanding the impact of the immune system on neoplastic cells is crucial to improve its effectiveness against cancer. The stratification of patients who might benefit from immunotherapy as well as the personalization of medicine have contributed to the discovery of new immunotherapeutic targets and molecules. In the present review, we discuss the mechanistic role of histone deacetylase inhibitors (HDACi) as potential immunomodulating agents to treat cancer. Our current understanding of the use of HDACi in combination with various immunotherapeutic approaches, such as immunomodulating agents and cancer vaccines, is also addressed. The potential clinical applications of the growing number of novel epigenetic drugs for cancer immunotherapy are widening, and some of these therapies are already in clinical trials.",
keywords = "Cancer, Epigenetics, Histone deacetylases, Immune evasion, Immunotherapy",
author = "Mariarosaria Conte and {De Palma}, Raffaele and Lucia Altucci",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.biocel.2018.03.004",
language = "English",
volume = "98",
pages = "65--74",
journal = "International Journal of Biochemistry and Cell Biology",
issn = "1357-2725",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - HDAC inhibitors as epigenetic regulators for cancer immunotherapy

AU - Conte, Mariarosaria

AU - De Palma, Raffaele

AU - Altucci, Lucia

PY - 2018/5/1

Y1 - 2018/5/1

N2 - In recent years, anti-tumor immunotherapy has shown promising results, and immune-oncology is now emerging as the fourth major wave in the treatment of tumors after radiotherapy, chemotherapy and molecular targeted therapy. Understanding the impact of the immune system on neoplastic cells is crucial to improve its effectiveness against cancer. The stratification of patients who might benefit from immunotherapy as well as the personalization of medicine have contributed to the discovery of new immunotherapeutic targets and molecules. In the present review, we discuss the mechanistic role of histone deacetylase inhibitors (HDACi) as potential immunomodulating agents to treat cancer. Our current understanding of the use of HDACi in combination with various immunotherapeutic approaches, such as immunomodulating agents and cancer vaccines, is also addressed. The potential clinical applications of the growing number of novel epigenetic drugs for cancer immunotherapy are widening, and some of these therapies are already in clinical trials.

AB - In recent years, anti-tumor immunotherapy has shown promising results, and immune-oncology is now emerging as the fourth major wave in the treatment of tumors after radiotherapy, chemotherapy and molecular targeted therapy. Understanding the impact of the immune system on neoplastic cells is crucial to improve its effectiveness against cancer. The stratification of patients who might benefit from immunotherapy as well as the personalization of medicine have contributed to the discovery of new immunotherapeutic targets and molecules. In the present review, we discuss the mechanistic role of histone deacetylase inhibitors (HDACi) as potential immunomodulating agents to treat cancer. Our current understanding of the use of HDACi in combination with various immunotherapeutic approaches, such as immunomodulating agents and cancer vaccines, is also addressed. The potential clinical applications of the growing number of novel epigenetic drugs for cancer immunotherapy are widening, and some of these therapies are already in clinical trials.

KW - Cancer

KW - Epigenetics

KW - Histone deacetylases

KW - Immune evasion

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85043490867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043490867&partnerID=8YFLogxK

U2 - 10.1016/j.biocel.2018.03.004

DO - 10.1016/j.biocel.2018.03.004

M3 - Review article

AN - SCOPUS:85043490867

VL - 98

SP - 65

EP - 74

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

SN - 1357-2725

ER -